Select Publications

Anderson GL et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-12. Abstract

Armstrong T et al. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2005;32(2):305-11. Abstract

Bertero C, Chamberlain WM. Breast cancer diagnosis and its treatment affecting the self: A meta-synthesis. Cancer Nurs 2007;30(3):194-202. Abstract

Boehmke MM, Dickerson SS. The diagnosis of breast cancer: Transition from health to illness. Oncol Nurs Forum 2006;33(6):1121-7. Abstract

Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract

Byar KL et al. Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. Oncol Nurs Forum 2006;33(1):E18-26. Abstract

Chorn N. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy. Oncol Nurs Forum 2006;33(2):265-72. Abstract

Consalvo KE et al. Treating one of our own. Clin J Oncol Nurs 2007;11(2):227-31. Abstract

Cuzick J et al. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006;94(4):460-4. Abstract

Ewer MS et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6. Abstract

Forbes JF. The use of early adjuvant aromatase inhibitor therapy: Contributions from the BIG 1-98 letrozole trial. Semin Oncol 2006;33(2 Suppl 7):2-7.  Abstract

Gobel BH. Nursing considerations of bevacizumab use in multiple tumor types. Oncol Nurs Forum 2007;34(3):693-701. Abstract

Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clin Breast Cancer 2006;6(Suppl 2):36-40. Abstract

Goss PE. Preventing relapse beyond 5 years: The MA.17 extended adjuvant trial. Semin Oncol 2006;33(2 Suppl 7):8-12. Abstract

Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53. Abstract

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract

Heidrich SM et al. Symptoms, symptom beliefs, and quality of life of older breast cancer survivors: A comparative study. Oncol Nurs Forum 2006;33(2):315-22. Abstract        

Jackisch C. HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy. Oncologist 2006;11(Suppl 1):34-41. Abstract

Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7. Abstract

Keller JS. Implementation of a prechemotherapy educational intervention for women newly diagnosed with breast cancer. Clin J Oncol Nurs 2006;10(1):57-60. Abstract

Limburg CE. Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer. Oncol Nurs Forum 2007:34(1):55-63. Abstract

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Oncology Cooperative Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

Mitchell SA et al. Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11(1):99-113. Abstract

Morales L et al. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 2005;17(6):559-65. Abstract

Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract

Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract

Payne J et al. Biomarkers, fatigue, sleep, and depressive symptoms in women with breast cancer: A pilot study. Oncol Nurs Forum 2006;33(4):775-83. Abstract                    

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract

Ravdin PM et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356(16):1670-4. Abstract

Ravdin PM et al. A sharp decrease in breast cancer incidence in the United States in 2003. San Antonio Breast Cancer Symposium 2006;Abstract 5.

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Ropka ME, Padilla G. Assessment of neutropenia-related quality of life in a clinical setting. Oncol Nurs Forum 2007;34(2):403-9. Abstract

Rossouw JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297(13):1465-77. Abstract

Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33. Abstract

Shumaker SA et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289(20):2651-62. Abstract

Siminoff LA et al. A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology 2006;15(11):1001-13. Abstract

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC  T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC  TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Sledge GW et al. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol 2006;4(21 Suppl 10):1-12. Abstract  

Sura W et al. Level of fatigue in women receiving dose-dense versus standard chemotherapy for breast cancer: A pilot study. Oncol Nurs Forum 2006;33(5):1015-21. Abstract

Table of Contents

Top of Page